Results of ALLO-715, an allogeneic BCMA-targeting CAR T cell therapy are published. Novel features to this product: ‼️ Has rituximab kill switch ‼️ Knockout of the T cell receptor alpha constant (TRAC) to reduce GVHD risk ‼️ Knockout CD52 /1 #mmsm w

Manni Mohyuddin @ManniMD1 · Jan 24, 2023

Excellent thread by @bdermanmd on ALLO-715, an allogeneic BCMA targeting CAR T cell therapy! #mmsm

Tweet Jan 24, 2023

by Ben Derman

Recommended by 1 person

1 mention